For emerging biotech firms, garnering capital can be a critical challenge. Hiring a dedicated Chief Financial Officer is typically unrealistically costly, especially when income are constrained. A fractional CFO https://phoebewmpp522928.mpeblog.com/73982786/fractional-cfo-a-biotech-funding-lifeline